The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts say.
PharmExec Blog
Follow Us
RSS
Bookstore
CETP Inhibitors: Blockbusters that Never Ran?